Coya Therapeutics (COYA) News Today $6.08 +0.22 (+3.75%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$6.08 0.00 (0.00%) As of 01/31/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period An ALS treatment wave is approaching, and this biotech CEO is ready to surfJanuary 27, 2025 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Stock, Short Interest ReportJanuary 21, 2025 | benzinga.comCoya Therapeutics expands investigational pipeline, advancement of COYA 303January 21, 2025 | markets.businessinsider.comCoya Therapeutics advances COYA 303 for inflammatory diseasesJanuary 21, 2025 | msn.comEXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory DiseasesJanuary 21, 2025 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Tuesday.January 21, 2025 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in DecemberCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 209,200 shares, a growth of 10.2% from the December 15th total of 189,800 shares. Based on an average daily volume of 92,500 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.4% of the company's shares are short sold.January 19, 2025 | marketbeat.comDelveInsight Business Research, LLP: Exosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsightJanuary 13, 2025 | finanznachrichten.deCoya Therapeutics, Inc. Common Stock (COYA) Institutional HoldingsDecember 23, 2024 | nasdaq.comD. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)D. Boral Capital reaffirmed a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday.December 18, 2024 | marketbeat.comD. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy RecommendationDecember 5, 2024 | msn.comD. Boral Capital Initiates Coverage on Coya Therapeutics (NASDAQ:COYA)D. Boral Capital began coverage on Coya Therapeutics in a report on Wednesday. They issued a "buy" rating and a $15.00 target price on the stock.December 4, 2024 | marketbeat.comCoya: COYA 301 – GLP-1 agonists combo synergistic in inflamation ameliorationNovember 21, 2024 | markets.businessinsider.comCoya Therapeutics files to sell 1.38M shares of common stock for holdersNovember 21, 2024 | markets.businessinsider.comCoya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder Buys 1,800 SharesNovember 15, 2024 | insidertrades.comHC Wainwright Has Optimistic Outlook of COYA FY2024 EarningsCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Coya Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.13) per share forNovember 14, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Insider Fred Grossman Purchases 2,710 SharesNovember 13, 2024 | insidertrades.comCoya Therapeutics' (COYA) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday.November 11, 2024 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPSCoya Therapeutics (NASDAQ:COYA - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15.November 9, 2024 | marketbeat.comCoya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comCoya Therapeutics Advances Pipeline for Neurodegenerative DiseasesNovember 7, 2024 | markets.businessinsider.comCoya Therapeutics Reports Q3 2024 Highlights and ProgressNovember 7, 2024 | markets.businessinsider.comCoya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday.November 7, 2024 | marketbeat.comWeekend Warriors and Dementia; Iron Chelation and Alzheimer's; Neuro Drug Costs RiseNovember 6, 2024 | msn.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 6.3% in OctoberCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 186,100 shares, an increase of 6.3% from the September 30th total of 175,000 shares. Currently, 1.3% of the company's shares are sold short. Based on an average daily volume of 50,700 shares, the days-to-cover ratio is currently 3.7 days.November 1, 2024 | marketbeat.comCoya Therapeutics Announces Leadership Change and New CEONovember 1, 2024 | markets.businessinsider.comCoya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive OfficerNovember 1, 2024 | finance.yahoo.comCoya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial ResultsOctober 31, 2024 | finance.yahoo.comPromising Phase II Trial Results Support Buy Rating for Coya Therapeutics’ Alzheimer’s TreatmentOctober 31, 2024 | markets.businessinsider.comCoya Therapeutics' (COYA) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday.October 30, 2024 | marketbeat.comCoya Therapeutics says Phase 2 LD-1L-2 study met primary, secondary endpointsOctober 30, 2024 | markets.businessinsider.comCoya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trialOctober 29, 2024 | reuters.comCoya Therapeutics Announces Closing of $10.0 Million Private PlacementOctober 23, 2024 | stockhouse.comCoya Therapeutics Announces $10M Private Placement to Advance PipelineOctober 22, 2024 | markets.businessinsider.comCoya Therapeutics to sell 1.379M shares at $7.25 in private placementOctober 22, 2024 | markets.businessinsider.comCoya Therapeutics Announces $10.0 Million Private PlacementOctober 22, 2024 | finance.yahoo.comCoya Therapeutics Shares Rise 9% After $10 Million Private PlacementOctober 22, 2024 | marketwatch.comExosomes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 15, 2024 | theglobeandmail.comCoya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100October 8, 2024 | finance.yahoo.comCoya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines ConferenceSeptember 24, 2024 | finance.yahoo.comResearch Analysts Issue Forecasts for Coya Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:COYA)Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Coya Therapeutics in a note issued to investors on Monday, September 16th. HC Wainwright analyst R. Selvaraju forecasts that the company will posSeptember 19, 2024 | marketbeat.comThis Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For MondaySeptember 17, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Coya Therapeutics (COYA) with Buy RecommendationSeptember 16, 2024 | nasdaq.comCoya Reports Anti-inflammatory Effect Of COYA 302 In Inflammatory Mouse Model Of Parkinson'sSeptember 16, 2024 | markets.businessinsider.comCoya Therapeutics (NASDAQ:COYA) Stock Quotes, Forecast and News SummarySeptember 16, 2024 | benzinga.comCoya Therapeutics (NASDAQ:COYA) Now Covered by HC WainwrightHC Wainwright started coverage on Coya Therapeutics in a report on Monday. They issued a "buy" rating and a $18.00 target price on the stock.September 16, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest UpdateCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 160,700 shares, a decrease of 9.1% from the July 31st total of 176,700 shares. Based on an average daily trading volume, of 55,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.1% of the company's shares are sold short.September 3, 2024 | marketbeat.comCoya Therapeutics to Present at Upcoming Healthcare ConferencesSeptember 3, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn SituationSeptember 3, 2024 | finance.yahoo.comCoya Therapeutics Names Arun Swaminathan Chief ExecutiveAugust 20, 2024 | marketwatch.com Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address COYA Media Mentions By Week COYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.400.69▲Average Medical News Sentiment COYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼32▲COYA Articles Average Week Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Esperion Therapeutics News Today ABIVAX Société Anonyme News Today Terns Pharmaceuticals News Today Precigen News Today Revance Therapeutics News Today REGENXBIO News Today Compass Therapeutics News Today Chimerix News Today Monte Rosa Therapeutics News Today Olema Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
